Physician profile

Mark S Rittenger

Pulmonary Disease · Grand Blanc, MI

NPI 1528011004

$449.46

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

Show all 24 companies
CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $14.19 2019
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $13.73 2019
Astrazeneca Pharmaceuticals Lp $13.38 2019
Circassia INC. $13.02 2019
Ekos Corporation $12.87 2019
Sunovion Pharmaceuticals INC. $12.59 2020
Regeneron Healthcare Solutions, INC. $12.45 2019
Teleflex LLC $11.64 2019
Gilead Sciences, INC. $11.17 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark S Rittenger

$449.46

in general payments reported 2019-2025

Years
2019-2020
Top company
Actelion Pharmaceuticals US, INC.

https://glasscript.com/doctor/205140/mark-s-rittenger

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.